COMPARISON OF SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BETWEEN HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

Ruqaiyah; Gontar Siregar; Masrul Lubis

Volume : VIII, Issue : II, February - 2019

COMPARISON OF SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BETWEEN HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

Ruqaiyah, Gontar Siregar, Masrul Lubis

Abstract :

Introduction: Hepatitis B virus infection is a major cause of acute hepatitis, chronic hepatitis, cirrhosis, and liver cancer in the world. The Hepatitis B virus is estimated to have infected more than 2 billion people until now. Based on the underlying disease, hepatitis B plays a role of up to 80% in all hepatocellular carcinoma events. Hepatocellular Carcinoma (HCC) is one of the important problems in the health sector because it can cause a variety of serious complications and require early treatment to improve prognosis and reduce mortality. Tumor development in HCC conditions will worsen cell hypoxia, which is known to be a Vascular Endothelial Growth Factor (VEGF). VEGF activity inducing condition is a protein that acts as the main regulator of angiogenesis

Method: The sample size for each study group are 30 people and 20 people. The sample were diagnosed with HCC and Chronic Hepatitis B virus infection and then a serum VEGF are performed. To display epidemiological data the subject of research used tabulation to show the descriptive picture. Data analyzed with SPSS 22nd.

Result: Based on the t–dependent test, the results showed that VEGF levels were significantly higher in the HCC group than in the chronic hepatitis B group (p–value = 0,0001).

Conclusion: Based on the results and discussion in this study, it can be concluded that serum VEGF levels are significantly higher in HCC patients than in chronic hepatitis B